Join us for an insightful webinar where leading experts in endocrinology and diabetes education delve into the transformative potential of GLP1-RA therapy in managing weight among individuals with Type 2 Diabetes Mellitus (T2DM).
The webinar will have live translation in Spanish and Portuguese.
Date: 6 May 2024
Time: 16:00 CET
Agenda
- Welcome & Introductions by Dr. Viral Shah
- Transformative Potential of GLP1-RA in Weight Management by Dr. Jaime Almandoz
- Patient Perspectives and Shared Decision-Making by Marissa Bowdler
- Q&A Session with all panelists
- Closing Remarks by Dr. Viral Shah
Learning Objectives
- Understand the transformative potential of GLP1-RA (Glucagon-Like Peptide-1 Receptor Agonists) in weight management for patients with Type 2 Diabetes Mellitus (T2DM).
- Gain insights into the mechanisms of action and clinical evidence supporting the use of GLP1-RA as a game-changer in weight control within the context of T2DM treatment.
- Explore the importance of patient perspectives and shared decision-making in optimizing treatment outcomes with GLP1-RA therapy.
- Engage in a collaborative Q&A session with expert panelists to address specific queries, challenges, and considerations related to GLP1-RA therapy and weight management in T2DM.
This educational activity is intended for an international audience of non-US and non-UK HCPs.
Faculty
Viral Shah, Associate Professor, Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus
Jaime Almandoz, Associate Professor of Internal Medicine and Medical Director of Weight Wellness Obesity Medicine Program·University of Texas Southwestern Medical Center
Jaime Almandoz, MD, MBA, MRCPI, FTOS is an Associate Professor of Internal Medicine and Medical Director of Weight Wellness Obesity Medicine Program at the University of Texas Southwestern Medical Center. Dr. Almandoz is a diplomate of the American Board of Obesity Medicine and board certified in Endocrinology and Internal Medicine.
Dr. Almandoz received his medical degree from the Royal College of Surgeons in Ireland, Internal Medicine Residency and Endocrinology Fellowship training at the Mayo Clinic, and a fellowship in Nutrition and Metabolic Diseases at UT Southwestern. Dr. Almandoz’s clinical and research interests include interdisciplinary programs for weight management, post-bariatric weight recurrence and disparities in obesity care.
Marissa Bowdler, PharmD, PGY-2 Ambulatory Care Resident at IU Health – Finerenone
Marissa Bowdler, PharmD, is a dedicated pharmacist with a passion for improving patient outcomes in diabetes, advanced heart failure management, and population health. She earned her Doctor of Pharmacy degree from St. John’s University College of Pharmacy and Health Sciences in Queens, NY.
Driven by a commitment to advancing pharmacy practice, Marissa has been involved in various professional organizations including the American Pharmacists Association (APhA), the American Society of Health-System Pharmacists (ASHP), and the New Jersey Society of Health-System Pharmacists (NJSHP). She actively contributes to the Interprofessional Universal Health (IUH) Committee, focusing on the value of pharmacist services.
Dr. Shah is an Associate Professor at the Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus. His research is focused on improving glycemic control and reducing complications, with a special interest in fracture prevention, in people with type 1 diabetes.
Dr. Shah has been the PI for many multicenter industry-sponsored, investigator-initiated, and nonprofit-funded clinical trials of diabetes technologies and therapeutics. He has been a part of landmark research such as REPLACE-BG, WISDM, Artificial pancreas Cambridge (ApCam), OP5 HCL, and Dexcom G6 pivotal that led to FDA approval of newer devices and changed the type 1 diabetes management. Moreover, his interest in understanding the effect of diabetes on bone fragility led to two NIH-funded studies investigating the effect of long-standing T1D on bone tissue material properties (AR075099) and factors affecting bone density (vBMD), bone mechanical properties in adults with type 1 diabetes (DK122554).